MedReleaf Corp. to Host First Quarter Fiscal 2018 Conference Call
MARKHAM, ON, July 26, 2017 /CNW/ - MedReleaf Corp. (TSX: LEAF), North America's first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products, today announced that it will hold a conference call to discuss its first quarter fiscal 2018 results on Monday, August 14, 2017 at 8:00 a.m. (ET). The call will be hosted by Neil Closner, Chief Executive Officer, and Igor Gimelshtein, Chief Financial Officer, followed by a question and answer period. MedReleaf will report its financial results in the morning prior to the call.
First Quarter Fiscal 2018 Conference Call Details:
| Date: |
Monday, August 14, 2017 |
| Time: |
8:00 a.m. (ET) |
| Dial in number: |
(647) 427-7450 or 1-888-231-8191 |
| Live webcast: |
Webcast will be archived for 90 days |
| Replay: |
1-855-859-2056 Available until August 21, 2017 |
| Replay passcode: |
59994102 |
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Final Long Form Prospectus dated May 30, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified producer of cannabis-based pharmaceutical products in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleafcanada
SOURCE MedReleaf Corp.
Dennis Fong, Investor Relations, [email protected], (416) 283-9930
Share this article